|
Jan 11
|
Novartis Pursuit of Cytokinetics Cools
|
|
Jan 10
|
Cytokinetics Deal Rumors Take Traders on White-Knuckle Ride
|
|
Jan 9
|
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
|
|
Jan 8
|
Novartis in Advanced Talks to Buy Cytokinetics
|
|
Jan 8
|
Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout.
|
|
Jan 8
|
Cytokinetics Stock Jumps After Report of Possible Novartis Deal
|
|
Jan 3
|
2 Biotechs That Could Get Bought Out in 2024
|
|
Jan 2
|
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 29
|
Director Wendall Wierenga Sells 10,000 Shares of Cytokinetics Inc (CYTK)
|
|
Dec 28
|
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
|
|
Dec 28
|
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
|
|
Dec 28
|
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
|
|
Dec 28
|
Company News for Dec 28, 2023
|
|
Dec 27
|
Gold nears $2100, biotech stocks on the move: Trending tickers
|
|
Dec 27
|
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
|
|
Dec 27
|
Cytokinetics Has Record Gain as Heart Drug Succeeds in Trial
|
|
Dec 27
|
UPDATE 1-Cytokinetics' heart disease drug meets main goal in study
|
|
Dec 27
|
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
|
|
Dec 26
|
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
|
|
Dec 15
|
11 Most Promising Biotech Stocks to Buy According to Analysts
|